{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:31:42Z","timestamp":1793305902414,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jhepr.2026.101968","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:32:49Z","timestamp":1785281569000},"page":"101968","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adjuvant capecitabine in resected biliary tract cancer: A real-world data from the BILCAP-Real study (ACABi multicenter cohort)"],"prefix":"10.1016","volume":"8","author":[{"given":"Claire","family":"No\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Henriques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4688-8765","authenticated-orcid":false,"given":"Brice","family":"Chanez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dewi","family":"Vernerey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5093-0212","authenticated-orcid":false,"given":"Thierry","family":"Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0193-9058","authenticated-orcid":false,"given":"Alice","family":"Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Assenat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-7741","authenticated-orcid":false,"given":"Julien","family":"Edeline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Heurgu\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8065-9635","authenticated-orcid":false,"given":"David","family":"Tougeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2735-6448","authenticated-orcid":false,"given":"Vincent","family":"Hautefeuille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Neuzillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00ebl","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Lagasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Tournigand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2435-4757","authenticated-orcid":false,"given":"Matthieu","family":"Delaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Hollebecque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Turpin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6072-7357","authenticated-orcid":false,"given":"Pauline","family":"Parent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2026.101968_bib1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrgastro.2016.51","article-title":"Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)","volume":"13","author":"Banales","year":"2016","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101968_bib2","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101968_bib3","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jhep.2019.03.013","article-title":"Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma","volume":"71","author":"Bertuccio","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101968_bib4","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jhep.2021.12.010","article-title":"Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry","volume":"76","author":"Izquierdo-Sanchez","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101968_bib5","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/ueg2.12154","article-title":"Risk factors, epidemiology and prognosis of cholangiocarcinoma in Finland","volume":"9","author":"Barner-Rasmussen","year":"2021","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.jhepr.2026.101968_bib6","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1245\/s10434-015-4472-9","article-title":"The impact of surgical margin status on long-term outcome after resection for intrahepatic cholangiocarcinoma","volume":"22","author":"Spolverato","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jhepr.2026.101968_bib7","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/jso.24165","article-title":"The true prognosis of resected distal cholangiocarcinoma","volume":"113","author":"Courtin-Tanguy","year":"2016","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.jhepr.2026.101968_bib8","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/jamasurg.2013.5137","article-title":"Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis","volume":"149","author":"Mavros","year":"2014","journal-title":"JAMA Surg"},{"key":"10.1016\/j.jhepr.2026.101968_bib9","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1200\/EDBK_160831","article-title":"Biliary tract cancer: epidemiology, radiotherapy, and molecular profiling","volume":"35","author":"Bridgewater","year":"2016","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.jhepr.2026.101968_bib10","first-page":"389","article-title":"Management and extent of resection for intrahepatic cholangiocarcinoma","volume":"18","author":"Carpizo","year":"2009","journal-title":"Surg Oncol Clin North America"},{"key":"10.1016\/j.jhepr.2026.101968_bib11","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/bjs.1800831217","article-title":"Outcome of treatment for distal bile duct cancer","volume":"83","author":"Fong","year":"1996","journal-title":"Br J Surg"},{"key":"10.1016\/j.jhepr.2026.101968_bib12","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1055\/s-2004-828895","article-title":"Surgical management of cholangiocarcinoma","volume":"24","author":"Jarnagin","year":"2004","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhepr.2026.101968_bib13","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/bjs.10776","article-title":"Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer","volume":"105","author":"Ebata","year":"2018","journal-title":"Br J Surg"},{"key":"10.1016\/j.jhepr.2026.101968_bib14","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.18.00050","article-title":"Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study","volume":"37","author":"Edeline","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.101968_bib15","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejca.2022.01.009","article-title":"Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studies","volume":"164","author":"Edeline","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhepr.2026.101968_bib16","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhepr.2026.101968_bib17","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1200\/JCO.21.02568","article-title":"Long-term outcomes and exploratory analyses of the randomized phase III BILCAP study","volume":"40","author":"Bridgewater","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.101968_bib18","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0140-6736(22)02038-4","article-title":"Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"401","author":"Nakachi","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jhepr.2026.101968_bib19","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1097\/HEP.0000000000000046","article-title":"Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial","volume":"77","author":"Jeong","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101968_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115342","article-title":"Adjuvant chemotherapy compared to observation in resected biliary tract cancers: survival meta-analysis of phase-III randomized controlled trials","volume":"220","author":"Akkus","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhepr.2026.101968_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/biomet\/asac054","article-title":"Propensity scores in the design of observational studies for causal effects","volume":"110","author":"Rosenbaum","year":"2023","journal-title":"Biometrika"},{"key":"10.1016\/j.jhepr.2026.101968_bib22","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-025-01250-9","article-title":"How hazard ratios can mislead and why it matters in practice","volume":"40","author":"Dumas","year":"2025","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.jhepr.2026.101968_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101936","article-title":"Current standards and future perspectives in adjuvant treatment for biliary tract cancers","volume":"84","author":"Lamarca","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jhepr.2026.101968_bib24","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhepr.2026.101968_bib25","doi-asserted-by":"crossref","first-page":"11S3","DOI":"10.1016\/S0007-4551(22)00463-5","article-title":"\u00c9tat des lieux des pratiques de prise en charge des cancers des voies biliaires en France : r\u00e9sultats de l\u2019enqu\u00eate nationale ACABi","volume":"109","author":"Delaye","year":"2022","journal-title":"Bull Cancer"},{"key":"10.1016\/j.jhepr.2026.101968_bib26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.dld.2024.06.032","article-title":"Real-life data on biliary tract cancers in France: the nested Amber study from the French ACABi GERCOR PRONOBIL retro-prospective, observational cohort","volume":"57","author":"Delaye","year":"2025","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhepr.2026.101968_bib27","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/bjc.1993.140","article-title":"Performance status assessment in cancer patients. An inter-observer variability study","volume":"67","author":"S\u00f8rensen","year":"1993","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhepr.2026.101968_bib28","doi-asserted-by":"crossref","first-page":"83","DOI":"10.21037\/apm.2016.03.02","article-title":"Inter-rater reliability in performance status assessment among health care professionals: a systematic review","volume":"5","author":"Chow","year":"2016","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.jhepr.2026.101968_bib29","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1186\/s12885-015-1498-0","article-title":"Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) \u2013 a randomized, multidisciplinary, multinational phase III trial","volume":"15","author":"Stein","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jhepr.2026.101968_bib30","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS4187","article-title":"ADJUBIL: a phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in adjuvant situation for biliary tract cancer","volume":"41","author":"Goetze","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16 supp","key":"10.1016\/j.jhepr.2026.101968_bib31","article-title":"A phase 3, randomized study of adjuvant rilvegostomig plus chemotherapy in resected biliary tract cancer: ARTEMIDE-Biliary01","volume":"42","author":"Bekaii-Saab","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926002399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926002399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T19:50:31Z","timestamp":1793303431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555926002399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S2589555926002399"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101968","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant capecitabine in resected biliary tract cancer: A real-world data from the BILCAP-Real study (ACABi multicenter cohort)","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101968","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101968"}}